Contacts

France : EIB and MedinCell sign a new €40 million loan agreement to support development of innovative treatments 

November 23, 2022

Download press release
  • The 40 million euros loan is intended for the development of treatments based on MedinCell’s proprietary long-acting injectable technology aiming at significantly enhance patient care and quality of life
  • This EIB investment is guaranteed by the European Fund for Strategic Investments, the central pillar of the Investment Plan for Europe 
  • This release follows an initial publication on 5 September 2022 (available here)

    Details of the loan agreement are available here

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.